SCHEMBL1899290

SCHEMBL1899290

COc1nccnc1I

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL607884 0.80 APLNR (0.40)
SCHEMBL1618985 0.75 GAA (0.38)
SCHEMBL22613006 0.72 APLNR (0.36)
SCHEMBL32689440 0.70
SCHEMBL422296 0.70
SCHEMBL111252 0.70 CYP2D6 (0.38)
SCHEMBL29483319 0.70 CYP2D6 (0.38)
SCHEMBL10699475 0.69
SCHEMBL30601875 0.69
SCHEMBL28279220 0.69 NFE2L2 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025224168-A1 ARYL SULFONE AND SULFANONE DERIVATIVES AS OREXIN RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2025-10-30 WO disclosed
US-20250195536-A1 BICYCLOOCTANE KRAS INHIBITORS INCYTE CORP (US) 2025-06-19 US disclosed
WO-2025129002-A1 BICYCLOOCTANE KRAS INHIBITORS INCYTE CORPORATION (US) 2025-06-19 WO disclosed
US-20210038607-A1 OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS KARUS THERAPEUTICS LIMITED (GB) 2021-02-11 US disclosed
US-20210038607-A1 OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS KARUS THERAPEUTICS LIMITED (GB) 2021-02-11 US disclosed
EP-3759106-A1 OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS Karus Therapeutics Ltd (GB) 2021-01-06 EP disclosed
CN-112004814-A Oxadiazolyl thiophene derivatives useful as inhibitors of histone deacetylase 卡鲁斯治疗有限公司 2020-11-27 CN disclosed
US-9938261-B2 Heterocyclic compounds and methods of use thereof AMBIT BIOSCIENCES CORPORATION (US) 2018-04-10 US disclosed
EP-2766359-B9 HETEROCYCLIC COMPOUNDS AND USE THEREOF AS MODULATORS OF TYPE III RECEPTOR TYROSINE KINASES AMBIT BIOSCIENCES CORP (US) 2017-04-05 EP disclosed
CN-104066730-B Heterocyclic compounds and their use as type III receptor tyrosine kinase modulators 埃姆比特生物科学公司 2017-03-08 CN disclosed
US-20130096113-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2013-04-18 US disclosed
WO-2013056070-A2 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2013-04-18 WO disclosed
US-20120309739-A1 AKT / PKB INHIBITORS ALMAC DISCOVERY LIMITED (GB) 2012-12-06 US disclosed
EP-2496566-A1 AKT / PKB INHIBITORS Almac Discovery Limited (GB) 2012-09-12 EP disclosed
WO-2011055115-A1 AKT / PKB INHIBITORS ALMAC DISCOVERY LIMITED (GB) 2011-05-12 WO disclosed
US-6552018-B1 As antitumor agents DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US disclosed
CN-1105707-C Pyrazole derivative DAIICHI SEIYAKU CO (JP) 2003-04-16 CN disclosed
US-6169086-B1 AN ANTITUMOR AGENT FOR TREATING TUMOR RESISTANT TO 5-FLUOROURACIL TYPE DRUGS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-01-02 US disclosed
EP-1022270-A1 PYRAZOLE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2000-07-26 EP disclosed
CN-1251578-A Pyrazole derivative DAIICHI SEIYAKU CO (JP) 2000-04-26 CN disclosed